Consolidated Entities (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Apr. 20, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Consolidated Entities
Receivable from related parties		$ 92,150		$ 92,150		$ 79,427	[1]
Cash balance		479,193		479,193		278,096	[1]
Total revenue		88,694	$ 65,755	246,318	$ 185,045
Total assets		922,256		922,256		724,826	[1]
Total operating expenses		4,264	4,962	9,982	12,324
Revenue from collaborative arrangements with a related party
Consolidated Entities
Total revenue		0	0	10,000	0
Theravance Respiratory Company, LLC
Consolidated Entities
Receivable from related parties		16,400		16,400		$ 14,400
Cash balance		41,400		41,400
Total revenue		16,400	11,200	48,100	28,400
Total operating expenses		600	$ 2,800	1,400	$ 2,900
Theravance Respiratory Company, LLC | Revenue from collaborative arrangements with a related party | MABA program
Consolidated Entities
Total revenue				10,000
Pulmoquine Therapeutics, Inc.
Consolidated Entities
Cash balance		4,300		4,300
Percentage of outstanding shares acquired	90.90%
Total assets		4,600		4,600
Other current assets		300		300
Total operating expenses		$ 1,100		$ 1,700
Pulmoquine Therapeutics, Inc. | Series A preferred stock
Consolidated Entities
Number of shares to be purchased under the securities purchase agreement	5,808,550
Payments for acquire variable interest	$ 5,000

[1] Consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements.